0000000000141362

AUTHOR

Joseph Gao

showing 1 related works from this author

Distinguishing the efficacy and sedative effects of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity diso…

2019

The present study investigated whether symptom reduction in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with guanfacine extended release (GXR) can be explained by sedative effects of the medication. Data from four double-blind, randomized, placebo-controlled, phase 3 trials of GXR monotherapy (1-7 mg/day; morning administration) in children (aged 6-12 years) and adolescents (aged 13-17 years) with ADHD were analyzed post hoc. Two studies used forced-dose titration and two used flexible-dose titration. Efficacy was determined using ADHD Rating Scale IV (ADHD-RS-IV) scores. Sedative treatment-emergent adverse events (TEAEs) included somnolence, sedati…

MalePediatricsmedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classSedationDrug Administration Schedule03 medical and health sciences0302 clinical medicineDouble-Blind MethodRating scalemedicineHumansHypnotics and SedativesAttention deficit hyperactivity disorderPharmacology (medical)ChildAdverse effectBiological PsychiatryMorningPsychiatric Status Rating ScalesPharmacologyDose-Response Relationship Drugbusiness.industrymedicine.diseaseGuanfacine030227 psychiatryGuanfacinePsychiatry and Mental healthTreatment OutcomeNeurologyAttention Deficit Disorder with HyperactivityDelayed-Action PreparationsSedativeFemaleNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgerySomnolenceFollow-Up Studiesmedicine.drugEuropean Neuropsychopharmacology
researchProduct